Genprex (NASDAQ:GNPX) and Sonnet BioTherapeutics (NASDAQ:SONN) Head-To-Head Review

Sonnet BioTherapeutics (NASDAQ:SONN) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sonnet BioTherapeutics and Genprex, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonnet BioTherapeutics	0	0	2	0	3.00
Genprex	0	0	1	0	3.00

Sonnet BioTherapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 4,025.98%. Genprex has a consensus price target of $10.00, suggesting a potential upside of 2,754.70%. Given Sonnet BioTherapeutics’ higher probable upside, equities analysts plainly believe Sonnet BioTherapeutics is more favorable than Genprex.

Volatility & Risk

Sonnet BioTherapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.57, indicating that its stock price is 157% less volatile than the S&P 500.

Institutional and Insider Ownership

9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Comparatively, 11.5% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Sonnet BioTherapeutics and Genprex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonnet BioTherapeutics	-11,187.19%	-398.45%	-142.16%
Genprex	N/A	-318.57%	-224.95%

Valuation and Earnings

This table compares Sonnet BioTherapeutics and Genprex”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonnet BioTherapeutics	$150,000.00	25.30	-$18.83 million	N/A	N/A
Genprex	N/A	N/A	-$30.86 million	N/A	N/A

Sonnet BioTherapeutics has higher revenue and earnings than Genprex.

Summary

Sonnet BioTherapeutics beats Genprex on 6 of the 10 factors compared between the two stocks.

About Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.